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Tau protein concentration in cerebrospinal fluid (CSF) is currently used as a sensitive
and specific biomarker for Alzheimer’s disease. Its detection currently relies on ELISA
but the perspective of using mass spectrometry (MS) to detect its different proteoforms
represents an interesting alternative. This is however an analytical challenge because
of its low concentration in the CSF, a biological fluid collected in small volume by
lumbar puncture, and with a high structural heterogeneity. To overcome these issues,
instead of using immunocapture as previously done, we rather relied on an original two
steps pre-fractionation technique of CSF: perchloric acid (PCA) followed by micro solid
phase extraction (µSPE). We could then measure seven tau trypsic peptides by Multiple
Reaction Monitoring (MRM) on a triple quadrupole mass spectrometer. Quantification
was performed using isotopically labeled 15N- recombinant tau protein as internal
standard and validated using CSF pools with low, medium, or high tau concentrations
(HTCs). Repeatability, intermediate precision, linearity, limit of quantification (LOQ), and
recovery were calculated for the different peptides. This new MRM assay, which allowed
for the first time CSF tau protein quantification without immunocapture, has important
potential application to follow tau metabolism in both diagnostic and therapeutic
research.
Keywords: Alzheimer’s disease, tau protein, human cerebrospinal fluid, LC-MS/MS, quantitative proteomic, triple
quadrupole
Introduction
Alzheimer’s disease (AD) is the most common form of dementia, a general term encompassing
loss of memory and cognitive functions interfering therefore with activities of daily living. With
35 million of patients worldwide, AD represents 50–80% of cases of dementia and is reaching
epidemic proportions in industrialized countries mainly because of the aging of the population.
Abbreviations: AD, Alzheimer Disease; CAV, Cell Accelerator Voltage; CE, Collision Energy; CSF, CerebroSpinal
Fluid; ELISA, Enzyme Linked ImmunoAssay; FA, Formic Acid; HLB, Hydrophilic-Lipophilic-Balanced; LOQ, Limit of
Quantification; MAPT, Microtubule-Associated Protein Tau; PCA, Perchloric Acid; TCA, Trifluoroacetic Acid; SPE, Solid
Phase Extraction; MRM-MS, Multiple Reaction Monitoring Mass Spectrometry; PTM, Post Translational Modifications.
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At neuro-pathological level, AD is characterized by the
presence in the brain parenchyma of amyloid plaques and
hyperphosphorylated tau (p-tau) proteins aggregated into
neurofibrillary tangles (Gabelle et al., 2010). Tau protein is
synthesized by a single microtubule-associated protein tau
(MAPT) gene (chromosome 17q21) in humans (James et al.,
2015) mainly expressed in neurons (Perrin et al., 2009). Tau
protein is known to bind neuronal microtubules, promote
their assembly, and stabilize them (Drechsel et al., 1992).
The hyperphosphorylation occurring in case of AD caused its
release frommicrotubules, destabilizing the axons, and triggering
neuronal death (Sergeant et al., 2005). Quantification of tau in
cerebrospinal fluid (CSF) is currently used as a sensitive and
specific biomarker for AD diagnosis (Andreasen and Blennow,
2005). However, the full quantification of tau in CSF remained an
analytical challenge. In fact, this protein has 6 different isoforms
(ranging from 352 to 441 amino acids), and is subject to many
different post-translational modifications like phosphorylation,
glycosylation, and oxidation (Hernandez and Avila, 2007).
Moreover, tau is present at very low concentration (Sjögren et al.,
2001; Blennow and Vanmechelen, 2003) in CSF which is a highly
complex matrix.
Currently, CSF tau quantification is performed in clinical daily
routine by immunoassays (ELISA). If immunoassays are sensitive
enough to detect low CSF tau concentrations, they present
some boundaries: poor linearity, lack of specificity in regards
to multiple tau proteoforms and no multiplexing. This is the
reason why mass spectrometry (MS) is an interesting alternative
in this context. In 2014, McAvoy et al. (2014) has published
a quantitative LC-MS/MS method to measure tau in CSF with
a sample preparation based on a immunoaffinity. Barthelemy
et al. recently quantified 22 tau peptides by high resolution
MS (Barthelemy, under review). Since this equipment is very
rarely available in clinical laboratories, we used the same sample
preparation protocol but quantification was performed on a triple
quadrupole mass spectrometer. In this work, we describe the set-
up of the first multiplex targeted MS quantification of tau in CSF
without the need of immunocapture. The workflow includes a
CSF protein precipitation and a solid phase extraction followed
by a trypsic digestion. Seven tau proteotypic peptides located in
different positions of the protein could be quantified by Selected
Reaction Monitoring. This new method has important potential
applications to follow tau metabolism in both diagnostic and
therapeutic research.
Materials and Methods
Reagents
Perchloric acid (PCA), trifluoroacetic acid (TCA), and hydrogen
peroxide (H2O2) were purchased from Sigma Aldrich (Saint
Quentin Fallavier, France). Ammonium bicarbonate and trypsin
were obtained from Fluka-Sigma Aldrich (Saint Quentin
Fallavier, France) and Promega (Charbonnieres, France),
respectively. Water, formic acid (FA), methanol (MeOH) were
all ULC-MS grade and purchased from Biosolve (Dieuze,
France). Normal Goat serum was obtained from Clinisciences
(Nanterre, France). Protein LoBind tube 1.5mL and Deepwell
plate 96/500µl Protein LoBind were purchased Eppendorf (Le
Pecq, France). Oasis HLB µElution Plate 30µm, was obtained
from Waters (Guyancourt, France). Polypropylene vials and
Zorbax 300 SB-C18 1 × 150mm 3.5µm were both purchased
from Agilent Technologies (Santa Clara, CA, USA).
Human CSF Samples and ELISA CSF Tau
Quantification
CSF samples were obtained from patients followed-up by the
Montpellier neurological and Clinical Research Memory Centers
(CMRR) for cognitive or behavioral disorders. They gave their
informed consent for research and for the storage of their
sample in an officially registered biological collection (#DC-
2008-417) of the certified NFS 96-900 biobank of the CHRU of
Montpellier (Ref: BB-0033-00031, www.biobanques.eu). CSF was
collected in polypropylene tubes under standardized conditions,
preferably between 9:00 a.m. and 1:00 p.m., to minimize the
influence of diurnal variation. Each CSF sample was sent to the
local laboratory within 4 h after collection and was centrifuged at
1000 g for 10min at 4◦C. CSF was aliquoted in polypropylene
tubes of 1.5mL and stored at −80◦C until further analysis.
Tau quantification was performed by ELISA InnoTest Tau from
Fujirebio diagnostics following manufacturer’s instructions.
Standards and Samples Preparation
Preparation of 14N and 15N recombinant tau protein
(441) standards
14N and 15N recombinant tau protein (441) were obtained
from Dr. Guy Lippens (UMR 8525, Lille Pasteur Institute,
France). Lyophilized standards were resuspended at 1 mg/mL
with ammonium bicarbonate 50mmol/L. The solution was then
aliquoted into 50µL in LoBind tubes and stored at −80◦C until
use. Concentration of 14N and 15N tau primary calibrators was
determined by amino acid analysis. Ten calibration standards
were prepared gravimetrically using an analytical balance model
Sartorius CPA224S-OCE (Sartorius Goettingen, Germany) by
adding a fixed amount of 15N tau to variable amounts of 14N tau.
Standards were diluted with 50mmol/L ammonium bicarbonate
and 1mmol/L BSA and then further diluted in 0.5% goat serum
so as to reach final concentration of 5 ng/mL for 15N tau while
that of 14N tau ranged from 0.3 to 32.1 ng/mL.
Series of 8–10 human CSF samples with tau concentrations
determined by ELISAweremixed to obtain 3 CSF pools with Low
Tau Concentration (LTC), Medium Tau Concentration (MTC),
and High Tau Concentration (HTC).
Precipitation, µSPE extraction and protein digestion
Sample extraction of tau peptides were performed according to
Barthelemy et al. (Barthelemy, under review). Briefly, 450µL
of CSF or 0.5% serum samples were mixed with 50µL of
15N-tau-441 (50 ng/mL) in a LoBind tube. Protein precipitation
was performed by adding 25µL of 70% PCA. Samples were
then vortexed, kept on ice for 15min before centrifugation at
17,000 g at 4◦C during 15min to obtain a clear supernatant.
Supernatants were acidified with 50µL of 1% trifluoroacetic
acid (TFA). SPE with a hydrophilic-lipophilic balance SPE
96-well plate was conditioned with 300µL of MeOH and
equilibrated with 500µL of 0.1% TFA. Samples were loaded
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and washed with 500µL of 0.1% TFA. For protein oxidation,
500µL of 3% FA and 3% H2O2 solution in water was loaded
on cartridge and kept 12 h at 4◦C. Thereafter, cartridge was
washed with 500µL of 0.1%TFA. Oxidized tau proteins were
eluted with 100µL of 35% acetonitrile 0.1% TFA. Extracts
were evaporated to dryness with a Speedvac instrument from
LabConco (Kansas City, MO, USA) and resuspended with 40µL
of 1 ng/µL trypsin solution in 50mM ammonium bicarbonate.
The digestion was performed for 24 h at 37◦C on a Thermomixer
R from Eppendorf (Hambourg, Germany) and stopped with 5µL
of 10% FA and stored at −20◦C prior to LC-MS/MS analysis
(Figure 1).
LC-MS/MS
Liquid chromatography (LC) separation
LC separation was carried out on a 1290 LC system (Agilent
technologies). Separation was performed with a reversed-phase
Zorbax 300 SB-C18 column maintained at 60◦C. The mobile
phases consisted in (A) 0.1% FA in water and (B) 0.1% FA in
MeOH. After an isocratic step of 2min at 2% B, a linear gradient
from 10 to 70% B was run over the next 13min with a flow rate
of 50µL/min. The column was then washed for 1min with 90%
B and re-equilibrated during 5min with 2% B. Eluent flow before
2min and after 15min was discarded with a divert valve to reduce
contamination of the mass spectrometer.
MS/MS analysis
Mass spectrometric detection was performed using a 6490
triple quadrupole with an ESI source operating in positive
mode and in dynamic MRM mode (Agilent technologies,
Waldbronn, Germany). The control of the LC-MS/MS was done
with MassHunter Software (Agilent technologies, Waldbronn,
Germany). The ESI spray was set up according to the following
settings: capillary tension 2500V, gas flow 16 L/min with
temperature of 140◦C, sheath gas flow 7 L/min with temperature
of 250◦C, nebulizer 40 psi. Precursor ions were transferred inside
the first quadrupole with high pressure ion funnel RF set to 150V
and low pressure in funnel RF set to 110V. Collision energies
(CE) and cell accelerator voltages (CA) were optimized for the
peptide transitions of interest. The Skyline 2.6 version was used to
conduct data treatment. All transitions per peptide were used as
quantifiers and were automatically detected on specific retention
time windows. LC-MS/MS were repeated 5 times for analytical
validation.
Method Validation
The calibration curve was established by linear regression and its
linearity was validated according to the criterion of a Pearson
correlation r2 > 0.99. The Limit of Quantification (LOQ) was
defined as the concentration of the lowest calibration point with
the relative standard deviation (RSD) of the area ratios 14N tau
peptide/15N tau peptide was less than 20%. Absence of memory
effects was tested by re-analyzing the calibrator point without
adding any 14N recombinant tau protein in the end of the
analytical sequence.
The intermediate precision of the entire protocol was
evaluated by preparing and measuring the 20 ng/mL calibration
standard over 6 different days. LC-MS repeatability was tested on
the 20 ng/mL calibration standard by injecting it 4 times in a row.
RSD was calculated from the area ratios 14N tau peptide/15N tau
peptide.
Recovery was evaluated by analyzing human CSF sample with
LTC spiked to a final concentration of 6.6 ng/mL of 14N tau.
Recovery was calculated by applying the following equation:
Recovery (%) = (Measured added concentration/Theoretical
added concentration)× 100.
Results
Method Development, Linearity, and Recovery
Starting from 22 validated peptides of CSF tau protein obtained
with high resolution MS in PRM mode (Barthelemy, under
review), 7 peptides (GAAPPGQK, SGYSSPGSPGTPGSR,
TPSLPTPPTREPK, TPSLPTPPTR, LQTPVPMPDLK,
IGSTENLK, SPVVSGDTSPR) were validated using triple
quadrupole in MRM mode (Table 1). One precursor ion and
2 products ion transitions were selected for the 22 peptides
previously validated in PRM. We kept the most intense
precursor ions (doubly charged) after optimization of the CE.
Each transition was verified using Skyline Software. For the
selection, three parameters were considered: signal intensities,
presence of interferences and concentration in CSF pools
(Table 1). The seven validated peptides (Figure 2) in human
CSF had repeatable retention times with a mean RSD of 1.53%
(Table 2).
Between successive LC-MS/MS analysis, no memory effect
phenomenon was observed. The calibration linearity was
assessed using 10 point calibration curves of 14N tau standard
spiked in normal goat serum 0.5%.MRM results showed linearity
over 2–32.7 ng/mL concentration range (Table 2). Calibration
curves were generated by linear regression analysis by plotting
the peak area ratios (14N tau/15N tau) vs. concentration
ratios for all measured peptides. The regression coefficients
were calculated above 0.98 for the 7 considered peptides.
Typical calibration curves are shown in Figure 3. The LOQs
were determined over 0.3–2 ng/mL range depending on the
peptide (Table 2). Calculated recovery rates were 121 ± 19%
for the 7 tau peptides and using the 6.6 ng/mL calibration
standard (n = 3). For the TPSLPTPPTR corresponding to
the epitope of the ELISA capture antibody, a recovery of 107%
was measured.
Precision Studies
Precision of the entire protocol (including both sample
preparation and LC-MS/MS analysis) was evaluated using these
samples. The RSD of the CSF pools processing was below 6% for
the 7 targeted peptides. LC-MS/MS analysis was repeatable with
RSD of less than 4% (n = 4).
Quantification of Tau Protein in CSF Pools
Tau concentrations measured in the 3 CSF pools (LTC, MTC,
and HTC) displayed different results for the 7 peptides (Table 2).
For the LTC, depending on the targeted peptide, MRM-
calculated concentrations ranged from 0.3 to 6.6 ng/mL, for
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FIGURE 1 | Sample extraction: 15N recombinant tau was spiked on CSF and proteins were then precipitated. Remaining proteins including tau in the
supernatant were extracted on HLB cartridges. During extraction, an oxidation step was performed to oxidize methionine. Extracts were dried and then enzymatically
digested by trypsin. Proteotypic peptides of tau protein were then quantified in the sample by LC-MS/MS.
TABLE 1 | Peptide selection: starting from 22 validated peptides of CSF tau protein obtained with high resolution mass spectrometry in PRM mode
(Barthelemy, under review), the 7 quantifed peptides (GAAPPGQK, SGYSSPGSPGTPGSR, TPSLPTPPTREPK, TPSLPTPPTR, LQTPVPMPDLK, IGSTENLK,
SPVVSGDTSPR) were selected by taking into account the three following parameters: signal intensities, presence of interferences, and concentration in
CSF pools.
Peptide sequence Peak intensity Interfered Increasing concentration in CSF pools MRM validation
GAAPPGQK 600 No Yes Yes
TPPAPK 2200 No No No
TPPSSGEPPK 200 Yes No No
IGSTENLK 100 No Yes Yes
SPVVSGDTSPR 100 No Yes Yes
SGYSSPGSPGTPGSR 300 No Yes Yes
VQIINK 400 Yes No No
SRTPSLPTPPTREPK 0 Yes No No
IGSLDNITHVPGGGNK 0 Yes No No
ESPLQTPTEDGSEEPGSETSDAK 0 Yes No No
TPSLPTPPTREPK 1200 No Yes Yes
STPTAEDVTAPLVDEGAPGK 0 Yes No No
TPSLPTPPTR 400 No Yes Yes
QAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQAR 0 Yes No No
HVPGGGSVQIVYKPVDLSK 0 Yes No No
TDHGAEIVYK 0 Yes No No
DQGGYTMHQDQEGDTDAGLK 0 Yes No No
LDLSNVQSK 0 Yes No No
QEFEVMEDHAGTYGLGDR 0 Yes No No
LQTAPVPMPDLK 100 No Yes Yes
HLSNVSSTGSIDM(diox)VDSPQLATLADEVSASLAK 0 Yes No No
KLDLSNVQSK 0 Yes No No
Bold and italics correspond to the 7 chosen tau peptides.
Underline characters (M) correspond to oxidized methionine.
the MTC from 1.6 to 12.5 ng/mL and for the HTC from 3.5
to 30.3 ng/mL. Calculated ratio between endogenous tau (14N)
and tau standard (15N) are presented in Figure 4, showing the
different concentrations obtained for each peptide in the three
CSF pools. For the peptide TPSLPTPPTR corresponding to
the epitope of the ELISA capture antibody, concentrations of
4.6 ng/mL for the LTC, 7.3 ng/mL for the MTC and 18.9 ng/mL
for the HTC were obtained.
ELISA Quantitation and Correlation with MRM
Tau concentration determined in the LTC, MTC, and HTC pools
using ELISA were 184 pg/mL, 399 pg/mL, and 1096 pg/mL,
respectively. For the 7 peptides, concentrations obtained using
MRM were highly correlated with those measured by ELISA
(r2 above 0.99) (see Figure 5 for the TPSLPTPPTR peptide as
an example). However, ELISA concentrations were 17–25 times
lower than those measured by MRM.
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FIGURE 2 | Chromatogram of calibration standard at 32.1 ng/mL in 0.5% normal goat serum after sample preparation.
Discussion
In this work, we presented for the first time an MRM based
multiplex assay for tau in the CSF that did not necessitate
any immuno-capture. Thanks to an adaptation of the “protein
standard for absolute quantification” (PSAQ) approach (Picard
et al., 2012), to an original two step purification protocol, and
to the latest generation of triple quadrupole MS analyzers, we
realized the tour-de-force of quantifying in parallel 7 proteotypic
peptides of the tau protein. Previous MS attempts to measure tau
in the CSF of patients were in fact limited to a few peptides and/or
rely on immuno-precipitation procedures that are potentially
subject to cross-reactivity and difficulty to obtain reproducible
results when using different batches of antibodies (Portelius
et al., 2008; McAvoy et al., 2014). Our method was successfully
applied to the analysis of CSF pools with different levels of tau
protein. Based on previous data obtained using the same sample
preparation workflow but using targeted high resolution mass
spectrometry (PRM), we validated 7 peptides using our triple
quadrupole (MRM) compared to the 22 beforehand validated
by PRM on a high resolution mass spectrometer. If MRM can
be considered to be less performing in terms of resolution, it
has multiple advantages compared to PRM. Mainly, the method
development is much easier, data amount generated are lighter
and the data processing is highly facilitated thanks to the Skyline
software. Additionally, our method can be much more easily be
transferred in a clinical environment where most popular mass
spectrometers are triple quadrupoles.
The MRM technology also provides several analytical
advantages compared with standard ELISA methods (Lehmann
et al., 2013). MRM is known to be highly selective and
specific (Lehmann et al., 2013) allowing to determine the
absolute concentration of the targeted protein, provided that
appropriate calibration standards are available. The MRM
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TABLE 2 | Method validation summary.
Peptide Position in the
tau protein
sequence
Linear
range
(ng/mL)
LOQ
(ng/mL)
Mean
retention
time (min)
Repeatability
RSD (%)
Recovery
at 6.6 ng/mL
(%)
Measured tau
concentration
LTC (ng/mL)
Measured tau
concentration
MTC (ng/mL)
Measured tau
concentration
HTC (ng/mL)
GAAPPGQK 156 – 163 0.3 – 32.7 0.3 5.91 1.5 117 6.6 12.5 30.3
SGYSSPGSPGTPGSR 195 – 209 2.0 – 32.7 2.0 8.37 0.6 154 3.6 7.6 20.9
TPSLPTPPTREPK 212 – 224 2.0 – 32.7 2.0 10.80 1.2 109 3.2 8.1 15.7
TPSLPTPPTR* 212 – 223 1.0 – 32.7 1.0 11.31 1.6 107 4.6 7.3 18.9
LQTPVPMPDLK 243 – 254 0.5 – 32.7 0.5 12.32 3.1 98 1 2.5 17.3
IGSTENLK 260 – 267 1.0 – 32.7 1.0 8.28 3.2 137 2.1 4.9 9.5
SPVVSGDTSPR 396 – 406 0.5 – 32.7 0.5 8.28 1.3 130 0.3 1.6 3.5
FIGURE 3 | Calibration curves of the 7 tau peptides.
absolute quantitation of the target protein takes benefit of the
advantages of isotope dilution MS (Huillet et al., 2012). Adding
a known amount of an isotopically labeled internal standard at
the beginning of sample preparation protocol makes it possible
to account for potential material non-recovery during sample
preparation, which results in better accuracy and precision.MRM
assay thus showed robust pre-analytical and analytical precision,
matching current clinical needs.
Interestingly, the value obtained for the quantification of tau
between the two approaches (MRM vs. ELISA) showed that
the concentration measured with our MRM-MS assay with the
TPSLPTPPTR peptide was around 17–25 times higher than that
with the ELISA test. This result is in modest agreement with the
work of McAvoy et al. (2014) who had found a correlation slope
of 1.8 between MSD and their IA-MS method using the same
peptide. The differences between the two LC-MS/MS approaches
are probably due to the different sample preparation techniques
(protein precipitation followed by SPE vs. immunoaffinity)
and the different standards used to establish the calibration
curves. The striking difference observed between LC-MS/MS
and ELISA results raises the question of what method is the
most accurate. However, a first evidence in favor of LC-MS/MS
is that our results were in pretty good agreement with those
published in McAvoy et al.: despite different sample preparation
procedures and different calibration standards were used, the
2 studies shown that for Tau concentrations below 500 pg/mL,
immunoassays are negatively biased against LC/MS. Another
evidence that immunoassays underestimated tau concentration
is that the concentration of our protein standard was 20 ng/mL
when measured by amino acid analysis, 21.4 ng/mL by LC-
MS/MS and around 2 ng/mL by ELISA (data not shown).
However, we didn’t check that the buffer in which standards
were dissolved (ammonium bicarbonate 50mM) is compatible
with Innogenetics ELISA. It can’t be ruled out that standards
and even our 3 CSF pools were not commutable for ELISA
tests, thereby introducing matrix effects that could explain
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FIGURE 4 | Ratio endogenous tau/15N tau in the three CSF pools (LTC, MTC, and HTC) for the 7 peptides. The scheme represents the localization of the 7
peptides on the tau protein.
FIGURE 5 | Correlation between MRM and ELISA results.
the very large discrepancy between LC-MS/MS and ELISA
results. In contrary, an argument in favor of ELISA is that
there were important differences in the relative levels of the 7
measured tau peptides measured by LC-MS/MS, depending on
their localization on the protein sequences; as illustrated in the
Figure 4. This was observed with small variations in the different
pools analyzed. This result can be explained by the strong
structural heterogeneity of the tau protein. Indeed, it has many
proteoforms (Smith and Kelleher, 2013): six isoforms (ranging
from 352 to 441 amino acids), truncated forms and forms
widely modified post-translationally by glycosylation, oxidation,
and phosphorylation at more than 80 sites (Iqbal et al., 2010;
Hanger et al., 2014). As phosphorylation and any other post-
translational modification of tau peptides induce a mass shift
that results in an underestimation of total tau concentration
measured by LC-MS/MS, it could be suspected that LC-MS/MS
results should have been even higher. This explains why total
tau concentrations measured using different peptides were not
in good agreement and suggests that total tau concentration
can only be measured using peptides that are neither subject
to any truncation nor post-translational modification. In this
sense, the peptide GAAPPGQK appears to be the best candidate
because it is short enough and it can’t be phosphorylated. This
hypothesis is supported by the fact that among the 7 considered
peptides, total tau concentration was the highest when estimated
with this peptide (see Table 2). Despite total tau concentrations
estimated using all the 7 peptides are in insufficient agreement
to support the use of peptides that can be phosphorylated,
the results obtained with the 6 other peptides also show an
excellent correlation between ELISA and LC-MS/MS, which
suggest that they can have a clinical relevancy as independent
biomarkers. However, to do the comparison with the 7 peptides,
all phosphorylated forms should have been measured. The
objective of measuring 7 peptides is not really to measure total
tau concentration but rather to use the 7 peptides as independent
biomarkers. As suggested in Höglund et al. (Höglund et al.,
2015), having insights into tau structural characterization and
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providing the opportunity to simultaneously quantify several
peptides whose concentration is directly proportional to that of
given tau proteoformswill make it possible to discover potentially
more predictive biomarkers of AD. A good example is P-Tau
(181), that is known to be the most relevant and predictive
proteoform of tau. This work thus illustrates the need but also
the future perspectives associated with the quantification of a
larger number of peptides. Especially, additional investigation
using in particular MRMmethods designed for phosphopeptides
detection (e.g., prefractionation using titanium columns) will be
needed to fully interpret our results and provide the analytical
methods needed to determine which proteoforms of the tau
protein are the most predictive of AD. Even if tau protein is
considered as a major biomarker of AD, the protein is also
increased when measured by ELISA in other tauopathies like
Creutzfeldt–Jakob Disease or Fronto Temporal Dementia (Green
et al., 1999; Wang et al., 2010). It will be interesting to use our
new method to determine whether the multiplex quantification
of the 7 tau peptides described in our study could help better
differentiating pathologies with increased tau in the CSF. In any
case, our MRM workflow realized without immunocapture in a
clinical laboratory environment represents a major improvement
to the state of the art and an interesting alternative and addition
to classical ELISA. Further work on large clinical cohorts will
be however needed to assess the clinical interest of this new
approach.
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